Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in mild to moderate psoriasis
NCT02529956Phase 1Completed
- Sponsor
- UCB
- Start
- Nov 2012
- Primary completion
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bimekizumab in plaque psoriasis (6 arms), sponsored by UCB. Primary endpoints: Treatment-Emergent Adverse Events at 20 weeks, Discontinuations due to Treatment-Emergent Adverse Events at 20 weeks and 1 more. Started Nov 2012; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02529956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529956.